Startup entity
All 1 tracked stories fall under one category: regulation. Amai Proteins is most often covered alongside FDA, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline.
Last mentioned: Feb 19, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: regulation. Amai Proteins is most often covered alongside FDA, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 2.4 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.3. Amai Proteins appears in 1 tracked Startup story from February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 70 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Amai Proteins. Shared-story counts are live from our verified record — not editorial picks.
Amai Proteins has received FDA GRAS approval for its designer protein sweetener, Sweelin, marking a pivotal regulatory milestone for the precision fermentation industry. This clearance allows the Israeli food-tech startup to begin large-scale commercialization in the U.S. food and beverage market.
Amai Proteins is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
